Clinically, and as predicted from our cell line data, we found that CML patients with the BIM deletion polymorphism had inferior first-line responses to standard dose IM compared to patients without the deletion [1]. This evidence concerns the gene BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive.